Skip to Content
Merck
  • Neuroprotective effect of mogrol against Aβ1-42 -induced memory impairment neuroinflammation and apoptosis in mice.

Neuroprotective effect of mogrol against Aβ1-42 -induced memory impairment neuroinflammation and apoptosis in mice.

The Journal of pharmacy and pharmacology (2018-12-27)
Gangling Chen, Caihong Liu, Guoliang Meng, Chunteng Zhang, Fang Chen, Susu Tang, Hao Hong, Chaofeng Zhang
ABSTRACT

Cognitive impairment is the main character of Alzheimer's disease (AD). This study mainly focused on whether mogrol, a tetracyclic triterpenoids compound of Siraitia grosvenorii Swingle, can ameliorate the memory impairment induced by Aβ1-42 . Memory impairment mice model was made by stereotactic intra-hippocampal microinjection of Aβ1-42 (410 pm/mouse). Mogrol (20, 40, 80 mg/kg) was given to mice by intragastric administration at 3 days after Aβ1-42 injection for totally 3 weeks. Morris water maze test and Y-maze test were operated to evaluate the therapeutic effect of morgrol on Aβ1-42 -induced memory impairments. Immunohistochemical analyses and Hoechst 33258 assay were used to evaluate effect of morgrol on Aβ1-42 -induced microglia overactivation and apoptotic response in hippocampus of mice. Western blotting assay was used to evaluate effect of mogrol on the Aβ1-42 -activated NF-κB signaling. Mogrol could significantly alleviate Aβ1-42 -induced memory impairments, inhibit Aβ1-42 -induced microglia overactivation and prevent Aβ1-42 -triggered apoptotic response in the hippocampus. Mogrol also could suppress Aβ1-42 -activated NF-κB signaling, reduce the production of proinflammatory cytokines. This study suggested that mogrol would ameliorate the memory impairment induced by Aβ1-42 , which is involved in anti-inflammation and anti-apoptosis in the brain.